CTI BIOPHARMA CORP

CTI BIOPHARMA CORP (CTIC)

$9.05

[object Object]

([object Object]%)

Market is closed - opens 7 PM, 02 Jun 2023

Insights on CTI BIOPHARMA CORP

  • Increasing Revenue

    Revenue is up for the last 5 quarters, 2.29M → 24.11M (in $), with an average increase of 35.0% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 3 quarters, -15.70M → -21.79M (in $), with an average decrease of 18.0% per quarter

Performance

  • $9.04
    $9.05
    $9.05
    downward going graph

    0.11%

    Downside

    Day's Volatility :0.11%

    Upside

    0.0%

    downward going graph
  • $4.01
    $9.05
    $9.05
    downward going graph

    55.69%

    Downside

    52 Weeks Volatility :55.69%

    Upside

    0.0%

    downward going graph

Returns

PeriodCTI BIOPHARMA CORPSector (Health Care)Index (Russel 2000)
3 Months
66.36%
0.7%
-6.8%
6 Months
51.34%
-8.3%
-6.0%
1 Year
52.36%
-1.9%
-4.6%
3 Years
66.36%
25.3%
25.9%

Highlights

Market Capitalization
1.2B
Book Value
- $0.19
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-0.54
PEG Ratio
0.0
Wall Street Target Price
10.49
Profit Margin
-91.38%
Operating Margin TTM
-73.54%
Return On Assets TTM
-28.58%
Return On Equity TTM
-1018.75%
Revenue TTM
75.8M
Revenue Per Share TTM
0.62
Quarterly Revenue Growth YOY
950.8%
Gross Profit TTM
50.4M
EBITDA
-53.6M
Diluted Eps TTM
-0.54
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.27
EPS Estimate Next Year
0.27
EPS Estimate Current Quarter
-0.12
EPS Estimate Next Quarter
-0.09

Analyst Recommendation

Buy
    92%Buy
    7%Hold
    0
    0%Sell
Based on 14 Wall street analysts offering stock ratings for CTI BIOPHARMA CORP(by analysts ranked 0 to 5 stars)
Based on 14 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
13
14
14
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 15.91%

Current $9.05
Target $10.49

Technicals Summary

Sell

Neutral

Buy

CTI BIOPHARMA CORP is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
CTI BIOPHARMA CORP
CTI BIOPHARMA CORP
85.07%
51.34%
52.36%
66.36%
66.36%
Moderna, Inc.
Moderna, Inc.
-4.27%
-29.63%
-10.94%
105.39%
586.61%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-8.82%
-3.37%
11.63%
22.7%
139.69%
Seagen, Inc.
Seagen, Inc.
-1.74%
61.71%
45.87%
23.07%
217.59%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-6.21%
0.88%
20.1%
12.88%
112.8%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
CTI BIOPHARMA CORP
CTI BIOPHARMA CORP
NA
NA
0.0
-0.27
-10.19
-0.29
0.0
-0.19
Moderna, Inc.
Moderna, Inc.
11.46
11.46
0.0
-1.9
0.27
0.12
0.0
49.12
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
19.72
19.72
9.01
41.59
0.19
0.1
0.0
219.38
Seagen, Inc.
Seagen, Inc.
NA
NA
18.53
-2.88
-0.23
-0.12
0.0
14.54
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
26.15
26.15
0.41
14.62
0.26
0.17
0.0
56.05
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
CTI BIOPHARMA CORP
CTI BIOPHARMA CORP
Buy
$1.2B
66.36%
NA
-91.38%
Moderna, Inc.
Moderna, Inc.
Buy
$49.1B
586.61%
11.46
31.77%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$79.5B
139.69%
19.72
33.81%
Seagen, Inc.
Seagen, Inc.
Hold
$36.7B
217.59%
NA
-31.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$83.8B
112.8%
26.15
35.4%

Institutional Holdings

  • State Street Corporation

    9.43%
  • Rubric Capital Management LP

    6.80%
  • Bvf Inc

    6.68%
  • BlackRock Inc

    5.35%
  • Stonepine Capital Management Llc

    4.96%
  • Vanguard Group Inc

    4.52%

Company Information

CTI BioPharma Corp. is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. The company concentrates its efforts on treatments that target blood-related cancers where there is an unmet medical need. In particular, we are focused on evaluating pacritinib, our sole product candidate currently in active late-stage development, for the treatment of adult patients with myelofibrosis. In addition, the company has recently started developing pacritinib for use in hospitalized patients with severe COVID-19, in response to the COVID-19 pandemic. The company's headquartered in Seattle, Washington.

Organization
CTI BIOPHARMA CORP
Employees
127
CEO
Dr. Adam R. Craig M.B.A., M.D., Ph.D.
Industry
Health Technology

FAQs